AAIC 2026: Epigenetic Mechanisms in Alzheimer's

Overview

The Alzheimer's Association International Conference (AAIC) 2026, held July 12-15, 2026, at Excel London, features sessions on epigenetic mechanisms in Alzheimer's disease. While specific session abstracts are not publicly available prior to the conference, the Basic Science Track includes sessions on molecular mechanisms of neurodegeneration, genetic risk factors, and neuroimmune pathways—areas where epigenetic research is prominently featured.

Relevant Session Tracks at AAIC 2026

Basic Science Track

The Basic Science Track covers several areas directly relevant to epigenetic mechanisms:

• Molecular mechanisms of neurodegeneration — including DNA methylation, histone modifications, and chromatin remodeling
• Genetic risk factors and protective variants — including epigenetic GWAS and eQTL studies
• Glial biology — microglia and astrocyte epigenetic regulation in neuroinflammation
• Neuroimmune pathways — TREM2, complement system, and inflammasome regulation through epigenetic modifications

ISTAART Professional Interest Areas

ISTAART (International Society to Advance Alzheimer's Research and Treatment) sessions include:

• Epigenetics PIA — focusing on DNA methylation, histone modifications, and non-coding RNA
• Bioinformatics and Data Science — covering multi-omics integration approaches
• Neuronal-Glial Interactions — epigenetic regulation of glial function

Key Topics in Current Epigenetic AD Research

...

Overview

The Alzheimer's Association International Conference (AAIC) 2026, held July 12-15, 2026, at Excel London, features sessions on epigenetic mechanisms in Alzheimer's disease. While specific session abstracts are not publicly available prior to the conference, the Basic Science Track includes sessions on molecular mechanisms of neurodegeneration, genetic risk factors, and neuroimmune pathways—areas where epigenetic research is prominently featured.

Relevant Session Tracks at AAIC 2026

Basic Science Track

The Basic Science Track covers several areas directly relevant to epigenetic mechanisms:

• Molecular mechanisms of neurodegeneration — including DNA methylation, histone modifications, and chromatin remodeling
• Genetic risk factors and protective variants — including epigenetic GWAS and eQTL studies
• Glial biology — microglia and astrocyte epigenetic regulation in neuroinflammation
• Neuroimmune pathways — TREM2, complement system, and inflammasome regulation through epigenetic modifications

ISTAART Professional Interest Areas

ISTAART (International Society to Advance Alzheimer's Research and Treatment) sessions include:

• Epigenetics PIA — focusing on DNA methylation, histone modifications, and non-coding RNA
• Bioinformatics and Data Science — covering multi-omics integration approaches
• Neuronal-Glial Interactions — epigenetic regulation of glial function

Key Topics in Current Epigenetic AD Research

DNA Methylation

Genome-wide studies have identified widespread DNA methylation changes in AD brain and blood. Key findings include:

• ANK1 hypermethylation — consistently observed in hippocampus and entorhinal cortex
• Blood-based biomarkers — DNA methylation signatures correlate with AD pathology
• Epigenetic age acceleration — where DNA methylation-based age exceeds chronological age, associated with increased AD risk

Recent meta-analysis by Smith et al. (2024) identified novel differentially methylated loci across cortex in AD brains.

Histone Modifications

Histone acetylation and methylation changes are prominent in AD:

• HDAC2 overexpression — represses synaptic plasticity genes
• H4K16ac loss — leads to chromatin compaction and gene silencing
• H3K9me3 alterations — leads to epigenetic derepression and cell cycle re-entry

Non-Coding RNAs

Multiple non-coding RNA classes are dysregulated in AD:

• miR-132 — most consistently downregulated, targets tau kinases
• miR-146a — upregulated, promotes neuroinflammation
• circular RNAs — emerging as biomarkers
• m6A RNA methylation — significantly altered in AD hippocampus

Recent research by Deng et al. (2024) revealed that m6A modification of promoter-antisense RNAs is profoundly rewired in AD, affecting 3D chromatin organization.

Therapeutic Implications

Epigenetic therapies represent a promising approach for AD:

HDAC inhibitors — selective compounds targeting HDAC2 or HDAC6

DNMT modulators — low-dose approaches for BDNF promoter demethylation

Epigenome editing — CRISPR-based tools for targeted epigenetic modification

miRNA therapeutics — miR-132 mimics and anti-miRNA oligonucleotides

Lifestyle interventions — exercise, diet, and stress reduction modify epigenetic marks

See Also

• [Epigenetic Mechanisms in Alzheimer's Disease](/mechanisms/epigenetics-ad)
• [DNA Methylation in AD](/mechanisms/ad-epigenetic-alterations-pathway)
• [Non-Coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
• [m6A RNA Modifications in CBS/PSP](/mechanisms/epitranscriptomics-rna-modifications-cbs-psp)
• [HDAC Proteins](/proteins/hdac6)
• [TREM2 Signaling](/mechanisms/trem2-signaling)

References

[AAIC 2026 Conference](https://aaic.alz.org) (2026)

[Smith et al., Nat Neurosci 2024](https://pubmed.ncbi.nlm.nih.gov/38688285/) — Meta-analysis of epigenome-wide association studies in AD

[Deng et al., Cell 2024](https://pubmed.ncbi.nlm.nih.gov/38976901/) — m6A rewiring in AD 3D nucleome

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | Pre-conference overview |
| Replication | N/A |
| Effect Sizes | N/A |
| Contradicting Evidence | N/A |
| Mechanistic Completeness | 30% |

Overall Confidence: 30%

Related AAIC 2026 Content

• [AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
• [AAIC 2026 Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)
• [AAIC 2026 Neuroinflammation](/events/aaic-2026/neuroinflammation)
• [AAIC 2026 Therapeutic Approaches](/events/aaic-2026/therapeutic-approaches)